TYME Technologies, Inc. to Host Conference Call and Webcast on Monday, November 8th at 8:30 AM ET
October 27 2021 - 4:30PM
Business Wire
- Company to report its second quarter fiscal
2022 financial results
TYME Technologies, Inc. (Nasdaq: TYME) (the “Company” or
“TYME”), an emerging biotechnology company developing cancer
metabolism-based therapies (CMBTs™), today announced that the
Company will report its second quarter 2022 financial results on
Monday, November 8, 2021 at 8:30 AM ET.
Richie Cunningham, Chief Executive Officer, and Frank Porfido,
Chief Financial Officer, will host a conference call and webcast as
follows:
Date:
Monday, November 8, 2021
Time:
8:30 AM ET
Toll-free (U.S.)
(866) 601-3896
International
(636) 812-6499
Conference ID
5953454
The webcast will be accessible on the Events &
Presentations page of the Investors section of the TYME
website, tymeinc.com, and will be archived for 90 days
following the event.
Following the Company’s presentation, there will be a Q&A
session. Management will address both live questions and those
submitted in advance via email to lwilson@insitecony.com. The
deadline to submit questions for the conference call is 5:00 PM ET
on November 4, 2021.
About TYME Technologies, Inc.
TYME is an emerging biotechnology company developing cancer
metabolism-based therapies (CMBTs™) that are intended to be broadly
effective across tumor types and have low toxicity profiles. Unlike
targeted therapies that attempt to regulate specific mutations
within cancer, the Company’s therapeutic approach is designed to
take advantage of a cancer cell’s innate metabolic weaknesses to
compromise its defenses, leading to cell death through oxidative
stress and exposure to the body’s natural immune system. The
Company is currently focused on developing its novel compound,
SM-88. The Company believes that early clinical results
demonstrated by SM-88 in multiple advanced cancers, including
pancreatic, prostate, sarcomas and breast, reinforce the potential
of our emerging CMBT™ pipeline.
For more information, visit www.tymeinc.com. Follow us on social
media: Facebook, LinkedIn, Twitter, YouTube and Instagram.
Forward-Looking Statements
In addition to historical information, this press release
contains forward-looking statements under the Private Securities
Litigation Reform Act that involve substantial risks and
uncertainties. The forward-looking statements contained in this
press release are based on management's current expectations, which
are subject to uncertainty, risks and changes in circumstances that
are difficult to predict and many of which are outside of TYME's
control. Factors that could cause actual results to differ
materially from these forward-looking statements include the
Company’s ability to successfully implement its clinical and other
plans, competitive and regulatory developments, and the factors
described in the section captioned “Risk Factors” of TYME’s Annual
Report on Form
10-K filed with the U.S. Securities and Exchange Commission
(“SEC”) on June 10, 2021, as well as subsequent reports and filings
from time to time with the SEC.
The information contained in this press release is as of release
date and TYME assumes no obligation to update forward-looking
statements contained in this release as a result of future events
or developments.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211027005875/en/
INVESTORS AND MEDIA: In-Site Communications Lisa M.
Wilson T: 212-452-2793 E: lwilson@insitecony.com
Tyme Technologies (NASDAQ:TYME)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tyme Technologies (NASDAQ:TYME)
Historical Stock Chart
From Apr 2023 to Apr 2024